Clinical Trial

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2023 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy，in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a "hot tumor" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05970302
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Tislelizumab, Bevacizumab, Oxaliplatin, Capecitabine, MSS/pMMR, Metastatic Colorectal Cancer (mCRC), RAS-mutated, First-Line
Enrollment 52 participants
Start Date 2023-07-07
Primary Completion 2025-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2023-08-01